Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PMOS to Evaluate the Compliance to Synagis (Palivizumab) Under Daily Pediatrician's Conditions in Premature Infants 33 - 35 wGA Over 2 Consecutive Respiratory Syncytial Virus (RSV) Seasons in Austria

Next Previous
Trial Profile

PMOS to Evaluate the Compliance to Synagis (Palivizumab) Under Daily Pediatrician's Conditions in Premature Infants 33 - 35 wGA Over 2 Consecutive Respiratory Syncytial Virus (RSV) Seasons in Austria

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 17 Jun 2014

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Palivizumab (Primary)
  • Indications Respiratory syncytial virus infections
  • Focus Therapeutic Use
  • Sponsors Abbott Laboratories

Most Recent Events

  • 19 Jan 2012 Actual patient number is 124 according to ClinicalTrials.gov.
  • 08 Aug 2011 Planned end date changed from 1 Jun 2011 to 1 Apr 2011 as reported by ClinicalTrials.gov .
  • 08 Aug 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top